Press Releases

February 21, 2013 - Neurovance Receives Notice of Allowance for Composition of Matter Patent and Initiates Clinical Trial of New SR Formulation of EB-1020

October 18, 2012 - Neurovance Closes $7M Series A1 Round for Development of EB-1020 for ADHD; Reports Phase 1 Clinical Trial Results

October 11, 2012 - Euthymics Completes Enrollment in TRIADE, its Advanced Trial of Amitifadine for Major Depressive Disorder

March 22, 2012 - Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD)

December 7, 2011 - Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 Into Clinical Trials For Adult ADHD

November 9, 2011 - Euthymics Bioscience, Inc. Appoints Dr. Randall Marshall, Leader in the Psychiatric Field, as Executive Director, Medical Affairs.

July 5, 2011 - Euthymics’ Lead Product Gains Generic Name, EB-1010 Now Called Amitifadine

June 28, 2011 - Euthymics Bioscience, Inc. Appoints Biotech Industry Veteran Thomas A. Shea as CFO and Announces Additional Senior Management Appointments

March 14, 2011 - Euthymics Bioscience Initiates TRIADE Trial for Major Depression

March 9, 2011 - Euthymics Bioscience Increases Series A Financing to Advance Second Program